Switch to:
Also traded in: Argentina, Germany, Mexico, Sweden, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.20
AZN's Cash-to-Debt is ranked lower than
84% of the 859 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.03 vs. AZN: 0.20 )
Ranked among companies with meaningful Cash-to-Debt only.
AZN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.19  Med: 0.97 Max: 10.55
Current: 0.2
0.19
10.55
Equity-to-Asset 0.19
AZN's Equity-to-Asset is ranked lower than
92% of the 788 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. AZN: 0.19 )
Ranked among companies with meaningful Equity-to-Asset only.
AZN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.19  Med: 0.43 Max: 0.59
Current: 0.19
0.19
0.59
Debt-to-Equity 1.75
AZN's Debt-to-Equity is ranked lower than
92% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. AZN: 1.75 )
Ranked among companies with meaningful Debt-to-Equity only.
AZN' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03  Med: 0.44 Max: 1.75
Current: 1.75
0.03
1.75
Debt-to-EBITDA 5.90
AZN's Debt-to-EBITDA is ranked lower than
67% of the 495 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.92 vs. AZN: 5.90 )
Ranked among companies with meaningful Debt-to-EBITDA only.
AZN' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.09  Med: 1.1 Max: 5.97
Current: 5.9
0.09
5.97
Interest Coverage 2.71
AZN's Interest Coverage is ranked lower than
88% of the 648 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 86.08 vs. AZN: 2.71 )
Ranked among companies with meaningful Interest Coverage only.
AZN' s Interest Coverage Range Over the Past 10 Years
Min: 2.71  Med: 7.23 Max: 20.36
Current: 2.71
2.71
20.36
Piotroski F-Score: 1
Altman Z-Score: 1.69
Beneish M-Score: -2.02
WACC vs ROIC
8.39%
7.45%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 7.52
AZN's Operating Margin % is ranked higher than
54% of the 801 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.97 vs. AZN: 7.52 )
Ranked among companies with meaningful Operating Margin % only.
AZN' s Operating Margin % Range Over the Past 10 Years
Min: 7.52  Med: 21.26 Max: 34.72
Current: 7.52
7.52
34.72
Net Margin % 11.31
AZN's Net Margin % is ranked higher than
73% of the 802 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.32 vs. AZN: 11.31 )
Ranked among companies with meaningful Net Margin % only.
AZN' s Net Margin % Range Over the Past 10 Years
Min: 4.64  Med: 17.26 Max: 29.52
Current: 11.31
4.64
29.52
ROE % 18.31
AZN's ROE % is ranked higher than
85% of the 832 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.94 vs. AZN: 18.31 )
Ranked among companies with meaningful ROE % only.
AZN' s ROE % Range Over the Past 10 Years
Min: 5.9  Med: 24.61 Max: 45.52
Current: 18.31
5.9
45.52
ROA % 3.86
AZN's ROA % is ranked higher than
57% of the 871 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.88 vs. AZN: 3.86 )
Ranked among companies with meaningful ROA % only.
AZN' s ROA % Range Over the Past 10 Years
Min: 2.2  Med: 8.87 Max: 18.22
Current: 3.86
2.2
18.22
ROC (Joel Greenblatt) % 30.00
AZN's ROC (Joel Greenblatt) % is ranked higher than
82% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.23 vs. AZN: 30.00 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AZN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 30  Med: 98.73 Max: 192.01
Current: 30
30
192.01
3-Year Revenue Growth Rate -0.50
AZN's 3-Year Revenue Growth Rate is ranked lower than
72% of the 689 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. AZN: -0.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AZN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -9.8  Med: 2.5 Max: 19.9
Current: -0.5
-9.8
19.9
3-Year EBITDA Growth Rate -11.60
AZN's 3-Year EBITDA Growth Rate is ranked higher than
59% of the 704 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. AZN: -11.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AZN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -29.4  Med: 5.6 Max: 28.2
Current: -11.6
-29.4
28.2
3-Year EPS without NRI Growth Rate 41.30
AZN's 3-Year EPS without NRI Growth Rate is ranked higher than
84% of the 663 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.90 vs. AZN: 41.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AZN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -48.8  Med: 17.3 Max: 48.5
Current: 41.3
-48.8
48.5
GuruFocus has detected 6 Warning Signs with AstraZeneca PLC AZN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AZN's 30-Y Financials

Financials (Next Earnings Date: 2019-02-01)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2018

AZN Guru Trades in Q1 2018

Ken Fisher 12,544,159 sh (+5.26%)
NWQ Managers 600,197 sh (+0.79%)
Sarah Ketterer 879,880 sh (+8.08%)
PRIMECAP Management 51,565,438 sh (+12.07%)
Steven Cohen 2,905,535 sh (+214.04%)
Jim Simons 1,031,000 sh (+892.30%)
David Dreman 180 sh (unchged)
Dodge & Cox 54,530,179 sh (-3.54%)
Murray Stahl 30,483 sh (-1.93%)
Jeremy Grantham 29,200 sh (-11.52%)
Pioneer Investments 1,165,717 sh (-0.40%)
» More
Q2 2018

AZN Guru Trades in Q2 2018

Ron Baron 130,500 sh (New)
Spiros Segalas 1,676,299 sh (New)
Ken Fisher 13,079,941 sh (+4.27%)
NWQ Managers 606,687 sh (+1.08%)
Sarah Ketterer 894,864 sh (+1.70%)
PRIMECAP Management 53,035,273 sh (+2.85%)
Dodge & Cox 52,774,809 sh (-3.22%)
Murray Stahl 27,263 sh (-10.56%)
Jeremy Grantham 28,700 sh (-1.71%)
Steven Cohen 2,802,046 sh (-3.56%)
Pioneer Investments 1,082,340 sh (-7.15%)
Jim Simons 985,100 sh (-4.45%)
» More
Q3 2018

AZN Guru Trades in Q3 2018

Spiros Segalas 10,472,097 sh (+524.72%)
Ken Fisher 13,516,724 sh (+3.34%)
PRIMECAP Management 55,399,286 sh (+4.46%)
Pioneer Investments 1,083,836 sh (+0.14%)
Sarah Ketterer 897,370 sh (+0.28%)
Ron Baron 194,523 sh (+49.06%)
Jeremy Grantham Sold Out
Jim Simons 27,200 sh (-97.24%)
Murray Stahl 25,263 sh (-7.34%)
NWQ Managers 571,541 sh (-5.79%)
Steven Cohen 757,400 sh (-72.97%)
Dodge & Cox 51,140,309 sh (-3.10%)
» More
Q4 2018

AZN Guru Trades in Q4 2018

Spiros Segalas 15,440,819 sh (+47.45%)
» More
» Details

Insider Trades

Latest Guru Trades with AZN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412 
Compare:NYSE:LLY, NYSE:BMY, XPAR:SAN, LSE:GSK, XTER:BAYN, TSE:4503, TSE:4519, TSE:4578, NYSE:ABBV, TSE:4568, NYSE:MRK, HKSE:01093, TSE:4151, TSE:4528, SHSE:600436, SHSE:600867, SZSE:002422, MIL:REC, BOM:500087, BOM:500302 » details
Traded in other countries:AZN.Argentina, ZEG.Germany, AZNN.Mexico, AZN.Sweden, AZN.Switzerland, AZN.UK, AZNCF.USA,
Headquarter Location:UK
AstraZeneca PLC belongs to the healthcare sector. The company develops and markets pharmaceutical products for various therapeutic classes such as gastrointestinal, cardiovascular, respiratory, cancer, immunology, and neuroscience.

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The company sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology, and neuroscience. The majority of sales come from international markets with the United States representing close to 30% of its sales.

Guru Investment Theses on AstraZeneca PLC

Dodge & Cox Funds Comments on AstraZeneca - Aug 01, 2017

AstraZeneca (NYSE:AZN), which is based in the United Kingdom, is a global pharmaceutical company with strengths in treatments for cancer, respiratory illnesses, cardiovascular problems, and infectious diseases. In the second half of 2016, the share price was under pressure due to concerns about recent and upcoming patent expirations for several of its major drugs. Despite this headwind, we added to the Fund’s holding in early 2017 after reaffirming our investment thesis.



The company’s long -term growth outlook is favorable given its robust new drug pipeline, particularly in oncology (cancer treatment). AstraZeneca has an attractive position in the revolutionary field of cancer immunotherapy, which harnesses the disease-fighting capabilities of the body’s immune system to attack cancerous tumors. We have conducted extensive due diligence, which included industry conferences and management meetings, and we continue to believe the immuno-oncology (IO) field holds great promise. Since the IO market is in its very early stages, sponsors and the scientific community are



investing heavily into understanding which tumors can be targeted with IO and which patients will be most responsive to IO treatments (i.e., biomarkers). We think the field will evolve rapidly over the next five to ten years as physicians develop a better understanding of how these drugs work, creating a massive revenue and profit opportunity. With a 4.3% dividend yield, the current valuation is reasonable at 17 times forward earnings and does not appear to reflect potential success from the immunotherapy drug pipeline. AstraZeneca shares represented 1.9% of the Fund on June 30.



From Dodge & Cox Stock Funds second quarter 2017 shareholder letter.



Check out Dodge & Cox latest stock trades

Dodge & Cox Comments on AstraZeneca - Feb 06, 2017

AstraZeneca (NYSE:AZN), which is based in the United Kingdom, is a global pharmaceutical company with strengths in treatment for cancer and respiratory, cardiovascular, and infectious diseases. The share price has been under pressure due to recent and upcoming patent expirations for major drugs. Despite this headwind, the long-term growth outlook is favorable because of the company’s robust new drug pipeline, particularly in oncology. AstraZeneca has an attractive position in the revolutionary field of cancer immunotherapy, which harnesses the disease -fighting capabilities of the body’s immune system to reduce and potentially eliminate cancer tumors. With a 4.6% dividend yield, the current valuation is reasonable and does not appear to reflect the potential success of the immunotherapy drug pipeline.





From Dodge & Cox's Global Stock Fund 4th quarter 2016 shareholder letter.



Check out Dodge & Cox latest stock trades

Top Ranked Articles about AstraZeneca PLC

Pyramid Biosciences Announces Exclusive Global License of AstraZeneca TRK Program for Dermatology and Inflammatory Diseases
Spiros Segalas Buys Alphabet, Tesla Guru's largest buys of the 3rd quarter
Spiros Segalas (Trades, Portfolio), also known as Sig, is the president, founding member, chief investment officer and portfolio manager of John Hancock Funds II and John Hancock Capital Appreciation Fund. Read more...
Report: Developing Opportunities within AstraZeneca, Manulife Financial, Infosys, Novartis AG, Black Hills, and Shell Midstream Partners — Future Expectations, Projections Moving into 2018
PhaseBio Secures $34 Million in Series D Financing
Seroquel Stepping Stone: How Luye Will Use Seroquel to Expand in Emerging Markets
AstraZeneca and the Revolving Door Biotech is not especially notorious as a revolving door industry, but perhaps investors should take a closer look, specifically at AstraZeneca
At the end of last week, director of the FDA’s Division of Pulmonary, Allergy, and Rheumatology Products Dr. Badrul Chowdhury announced his move to British big pharma firm AstraZeneca PLC (NYSE:AZN) as the new vice president of research and development at its biologics unit. Read more...

Ratios

vs
industry
vs
history
PE Ratio 38.95
AZN's PE Ratio is ranked lower than
71% of the 557 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.77 vs. AZN: 38.95 )
Ranked among companies with meaningful PE Ratio only.
AZN' s PE Ratio Range Over the Past 10 Years
Min: 6.03  Med: 13.42 Max: 99.64
Current: 38.95
6.03
99.64
Forward PE Ratio 21.23
AZN's Forward PE Ratio is ranked lower than
55% of the 111 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.60 vs. AZN: 21.23 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 38.95
AZN's PE Ratio without NRI is ranked lower than
70% of the 556 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.20 vs. AZN: 38.95 )
Ranked among companies with meaningful PE Ratio without NRI only.
AZN' s PE Ratio without NRI Range Over the Past 10 Years
Min: 6.03  Med: 13.42 Max: 99.64
Current: 38.95
6.03
99.64
Price-to-Owner-Earnings 187.54
AZN's Price-to-Owner-Earnings is ranked higher than
59% of the 324 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 31.95 vs. AZN: 187.54 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
AZN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.41  Med: 12 Max: 208.89
Current: 187.54
5.41
208.89
PB Ratio 7.73
AZN's PB Ratio is ranked lower than
88% of the 819 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.64 vs. AZN: 7.73 )
Ranked among companies with meaningful PB Ratio only.
AZN' s PB Ratio Range Over the Past 10 Years
Min: 2.3  Med: 3.78 Max: 8.61
Current: 7.73
2.3
8.61
PS Ratio 4.42
AZN's PS Ratio is ranked lower than
64% of the 775 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. AZN: 4.42 )
Ranked among companies with meaningful PS Ratio only.
AZN' s PS Ratio Range Over the Past 10 Years
Min: 1.61  Med: 2.44 Max: 4.92
Current: 4.42
1.61
4.92
EV-to-EBIT 50.05
AZN's EV-to-EBIT is ranked lower than
86% of the 572 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.85 vs. AZN: 50.05 )
Ranked among companies with meaningful EV-to-EBIT only.
AZN' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.3  Med: 10.05 Max: 61
Current: 50.05
4.3
61
EV-to-EBITDA 31.18
AZN's EV-to-EBITDA is ranked lower than
66% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.24 vs. AZN: 31.18 )
Ranked among companies with meaningful EV-to-EBITDA only.
AZN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.5  Med: 7.35 Max: 34.1
Current: 31.18
3.5
34.1
EV-to-Revenue 5.29
AZN's EV-to-Revenue is ranked lower than
67% of the 795 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.24 vs. AZN: 5.29 )
Ranked among companies with meaningful EV-to-Revenue only.
AZN' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.6  Med: 2.6 Max: 5.8
Current: 5.29
1.6
5.8
Shiller PE Ratio 21.63
AZN's Shiller PE Ratio is ranked higher than
69% of the 252 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.75 vs. AZN: 21.63 )
Ranked among companies with meaningful Shiller PE Ratio only.
AZN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 3.56  Med: 5.46 Max: 24.05
Current: 21.63
3.56
24.05
Current Ratio 0.86
AZN's Current Ratio is ranked lower than
94% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.39 vs. AZN: 0.86 )
Ranked among companies with meaningful Current Ratio only.
AZN' s Current Ratio Range Over the Past 10 Years
Min: 0.64  Med: 1.46 Max: 2.01
Current: 0.86
0.64
2.01
Quick Ratio 0.66
AZN's Quick Ratio is ranked lower than
93% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.87 vs. AZN: 0.66 )
Ranked among companies with meaningful Quick Ratio only.
AZN' s Quick Ratio Range Over the Past 10 Years
Min: 0.54  Med: 1.2 Max: 1.83
Current: 0.66
0.54
1.83
Days Inventory 252.37
AZN's Days Inventory is ranked lower than
88% of the 755 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 119.80 vs. AZN: 252.37 )
Ranked among companies with meaningful Days Inventory only.
AZN' s Days Inventory Range Over the Past 10 Years
Min: 88.45  Med: 126.46 Max: 252.37
Current: 252.37
88.45
252.37
Days Sales Outstanding 96.27
AZN's Days Sales Outstanding is ranked higher than
79% of the 770 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 81.76 vs. AZN: 96.27 )
Ranked among companies with meaningful Days Sales Outstanding only.
AZN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40.99  Med: 68.49 Max: 96.27
Current: 96.27
40.99
96.27
Days Payable 911.05
AZN's Days Payable is ranked higher than
91% of the 758 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 76.32 vs. AZN: 911.05 )
Ranked among companies with meaningful Days Payable only.
AZN' s Days Payable Range Over the Past 10 Years
Min: 128.94  Med: 195.78 Max: 911.05
Current: 911.05
128.94
911.05

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.83
AZN's Dividend Yield % is ranked higher than
85% of the 752 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.54 vs. AZN: 3.83 )
Ranked among companies with meaningful Dividend Yield % only.
AZN' s Dividend Yield % Range Over the Past 10 Years
Min: 3.24  Med: 4.61 Max: 6.88
Current: 3.83
3.24
6.88
Dividend Payout Ratio 1.46
AZN's Dividend Payout Ratio is ranked lower than
94% of the 477 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.30 vs. AZN: 1.46 )
Ranked among companies with meaningful Dividend Payout Ratio only.
AZN' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.37  Med: 0.78 Max: 2.89
Current: 1.46
0.37
2.89
3-Year Dividend Growth Rate 4.40
AZN's 3-Year Dividend Growth Rate is ranked lower than
59% of the 299 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.40 vs. AZN: 4.40 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
AZN' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 9.2 Max: 41.2
Current: 4.4
0
41.2
Forward Dividend Yield % 3.83
AZN's Forward Dividend Yield % is ranked higher than
83% of the 719 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.66 vs. AZN: 3.83 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 4.77
AZN's 5-Year Yield-on-Cost % is ranked higher than
83% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.12 vs. AZN: 4.77 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
AZN' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 4.04  Med: 5.74 Max: 8.57
Current: 4.77
4.04
8.57
3-Year Average Share Buyback Ratio -0.10
AZN's 3-Year Average Share Buyback Ratio is ranked higher than
86% of the 571 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -5.30 vs. AZN: -0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AZN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -23.3  Med: 0.8 Max: 5
Current: -0.1
-23.3
5

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 3.09
AZN's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
71% of the 374 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.11 vs. AZN: 3.09 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
AZN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.48  Med: 2.06 Max: 17.21
Current: 3.09
0.48
17.21
Price-to-Median-PS-Value 1.81
AZN's Price-to-Median-PS-Value is ranked lower than
86% of the 743 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.94 vs. AZN: 1.81 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AZN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.59  Med: 1.24 Max: 2.83
Current: 1.81
0.59
2.83
Earnings Yield (Greenblatt) % 2.00
AZN's Earnings Yield (Greenblatt) % is ranked lower than
57% of the 867 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.31 vs. AZN: 2.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AZN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.6  Med: 9.95 Max: 23.2
Current: 2
1.6
23.2
Forward Rate of Return (Yacktman) % -2.07
AZN's Forward Rate of Return (Yacktman) % is ranked lower than
70% of the 421 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.96 vs. AZN: -2.07 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
AZN' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -17.1  Med: 9.9 Max: 26.8
Current: -2.07
-17.1
26.8

More Statistics

Revenue (TTM) (Mil) $21,450.00
EPS (TTM) $ 0.96
Beta0.64
Volatility16.24%
52-Week Range $32.69 - 41.78
Shares Outstanding (Mil)2,534.08 (ADR)

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 22,172 23,910 26,840
EBIT (Mil $) 4,406 4,884 7,307
EBITDA (Mil $) 6,695 7,159 9,823
EPS ($) 1.05 1.08 1.25
EPS without NRI ($) 1.05 1.08 1.25
EPS Growth Rate
(Future 3Y To 5Y Estimate)
3.29%
Dividends per Share ($) 1.40 1.40 1.44

Piotroski F-Score Details

Piotroski F-Score: 11
Positive ROAY
Positive CFROAN
Higher ROA yoyN
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}